Jove
Visualize
Contact Us

Related Experiment Videos

Antithrombin III concentrates in intensive care.

W Bernhardt, A Nováková-Banet

    La Ricerca in Clinica E in Laboratorio
    |January 1, 1983
    PubMed
    Summary

    Antithrombin III concentrates enhance plasma

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report.

    Atherosclerosis·2024
    Same author

    Issues relating to the release of proprietary information and data for use in the validation of alternative methods.

    Alternatives to laboratory animals : ATLA·2015
    Same author

    Hypoxia-inducible factors and tubular cell survival in isolated perfused kidneys.

    Kidney international·2006
    Same author

    Genomic plasticity and melanoma formation in the fish Xiphophorus.

    Marine biotechnology (New York, N.Y.)·2004
    Same author

    Proliferation and survival of mammary carcinoma cells are influenced by culture conditions used for ex vivo expansion of CD34(+) blood progenitor cells.

    Blood·1999
    Same author

    Minimal residual disease in autologous hematopoietic harvests from breast cancer patients.

    Annals of oncology : official journal of the European Society for Medical Oncology·1998
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Biochemistry
    • Hematology
    • Critical Care Medicine

    Background:

    • Heparin's anticoagulant effect is limited by existing antithrombin III (ATIII) levels.
    • Increasing inhibitory potential is crucial for managing coagulation disorders.
    • ATIII substitution offers a method to boost plasma's natural anticoagulant capacity.

    Purpose of the Study:

    • To evaluate the therapeutic potential of Antithrombin III (ATIII) concentrates.
    • To assess the role of ATIII substitution in critical care settings.
    • To explore the efficacy of ATIII in preventing thrombotic complications.

    Main Methods:

    • Administration of Antithrombin III concentrates.
    • Monitoring of coagulation parameters and clinical outcomes.
    • Application in patients with severe conditions like liver failure and sepsis.

    Main Results:

    • ATIII concentrates rapidly increase plasma inhibitory potential.
    • Substitution of ATIII aided intensive care for patients with liver failure, amniotic fluid embolism, heavy bleedings, and septicemia.
    • Disseminated intravascular coagulation was prevented or interrupted, with potential avoidance of shock lung and kidney.

    Conclusions:

    • Antithrombin III concentrates provide a viable therapeutic option for immediate enhancement of plasma's inhibitory capacity.
    • ATIII substitution is beneficial in critical care, particularly for preventing thrombosis and managing coagulation disorders.
    • Therapeutic plasmapheresis can be performed safely with ATIII substitution, mitigating thrombotic risks.

    Related Experiment Videos